Blockade of immune regulatory molecules identified in this study, including B7-H4, VISTA, CD73, PD-L2, and TIM-3 can potentially offer a treatment strategy to reinstate host immune response against HCC and ultimately tumor regression. This evidence concerns the gene HAVCR2 and hepatocellular carcinoma.